Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jonathan Bloomberg

Child & Adolescent Psychiatry Northbrook, IL Medical Doctor

NPI 1336322924 CMS profile 1113241

950 Skokie Blvd, #307, Northbrook, IL 60062

Open in the dashboard

General payments

$3,448

288 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jonathan Bloomberg of Northbrook, IL is reported in the CMS Open Payments database as having received $3,448 across 288 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Child & Adolescent Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $783 53
2024 General $57 9
2023 General $112 15
2022 General $210 13
2021 General $171 18
2020 General $389 20
2019 General $1,725 160

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jonathan Bloomberg
  • Child & Adolescent Psychiatry median
  • Middle half of Child & Adolescent Psychiatry
  • National median

In program year 2025, general payments to Jonathan Bloomberg were reported at $783. Among 1,601 Child & Adolescent Psychiatry profiles paid that year, the median was $132 and the middle half received between $41 and $474.

Show as a table
Year Jonathan Bloomberg Child & Adolescent Psychiatry median Middle half National median
2019 $1,725 $129 $42–$419 $163
2020 $389 $81 $28–$226 $114
2021 $171 $115 $31–$326 $132
2022 $210 $124 $40–$382 $149
2023 $112 $130 $45–$420 $160
2024 $57 $141 $42–$490 $164
2025 $783 $132 $41–$474 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $364 42 payments
  2. Otsuka America Pharmaceutical, Inc. $312 35 payments
  3. Allergan Inc. $300 21 payments
  4. Lundbeck LLC $263 16 payments
  5. Janssen Pharmaceuticals, Inc $223 23 payments
  6. Neos Therapeutics, LP $216 19 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $173 10 payments
  8. Teva Pharmaceuticals USA, Inc. $161 7 payments
  9. Vertical Pharmaceuticals, LLC $150 9 payments
  10. ITI, Inc. $145 6 payments
  11. Other $1,141 100 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,401 287 payments
  2. Education $47 1 payment
Products named General payments · program years 2019–2025
  1. VRAYLAR Neuroscience $497 45 payments
  2. REXULTI Psychiatry $312 35 payments
  3. REXULTI Psychiatry $198 10 payments
  4. Adzenys XR-ODT $194 18 payments
  5. COTEMPLA XR-ODT $194 18 payments
  6. VYVANSE $170 18 payments
  7. SPRAVATO $168 16 payments
  8. AUSTEDO $161 7 payments
  9. VRAYLAR Neuroscience $153 16 payments
  10. LATUDA $139 16 payments
  11. Other $1,735 127 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

180

Median for Neuropsychiatry: 88

Drug cost

$10,353

Median for Neuropsychiatry: $2,689

Branded share of claims

14.4%

Median for Neuropsychiatry: 16.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Qelbree Viloxazine Hcl Brand 13 $8,957
Gabapentin Generic 31 $344
Duloxetine Hcl Generic 26 $230
Bupropion Xl Bupropion Hcl Brand 13 $184
Escitalopram Oxalate Generic 24 $176
Mirtazapine Generic 12 $174
Alprazolam Generic 17 $131
Fluoxetine Hcl Generic 19 $119
Sertraline Hcl Generic 11 $22
Trazodone Hcl Generic 14 $13

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,891 Part D prescribers listed as Neuropsychiatry; they describe a distribution and say nothing about conduct.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
WAKIX
  • Harmony Biosciences LLC $18
$18 — —
VRAYLAR
  • AbbVie, Inc. $15
$15 — —
COBENFY
  • E.R. Squibb & Sons, L.L.C. $14
$14 — —
Azstarys
  • Corium, Inc. $10
$10 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

288 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Child & Adolescent Psychiatry in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record